연구자 간 교류.영국.가상인체 기술.Exchange of researchers.UK.Virtual human body.
초록 ▼
본 과제의 목적은 한국 과학 기술원 (KAIST)과 영국 Cambridge University의 과학자들의 협력연구 도모이다. 본 과제를 통하여, KAIST와 Cambridge의 연구진들은 이메일, 통화, 화상통화, 화상회의, ...
본 과제의 목적은 한국 과학 기술원 (KAIST)과 영국 Cambridge University의 과학자들의 협력연구 도모이다. 본 과제를 통하여, KAIST와 Cambridge의 연구진들은 이메일, 통화, 화상통화, 화상회의, 대면 회의, 심포지엄, 워크샵 등 다양한 방법으로 교류 하였다. 이후에도 이러한 협력을 지속하기 위하여, CDA(confidential disclosure agreement)를 작성하였다.
( 출처: 보고서 요약서 3p )
Abstract ▼
□ Purpose&Contents ○ The purpose of this collaborative research is to develop a joint research project on the analysis of drug ...
□ Purpose&Contents ○ The purpose of this collaborative research is to develop a joint research project on the analysis of drug efficacy and side effect using artificial intelligence virtual human technology by KAIST and Cambridge University(Cambridge Univ.). And to discover mutually complementary promising technologies.
□ Results ○ Discussion of how to collaborate - Discussed research ideas and collaborative research methods that could be conducted at MTI by utilizing BSRC's technology (CODA, COCONUT) through e-mail. ○ Visits between countries - The researchers in Cambridge, Tony and Dr. Han NamSik, visited Seoul, Korea, and met the researcher in KAIST, professor Lee Doheon and Shin Moonshik. - The researchers in KAIST attended a symposium held at Cambridge to introduce CODA and COCONUT technique. They also interacted with other institutions that interacted with Cambridge. ○ Online meeting - Cambride researchers and collaborating organizations including KAIST held online video conferences. ○ Documentation of cooperation The BSRC in KAIST participated in the Milner Consortium. CDA (confidential disclosure agreement) was made.
□ Expected Contribution ○ KAIST has expertise in bioinformatics such as virtual human technologies. The University of Cambridge has a direct link to the Wellcome Trust Sanger Institute's pharmaceutical companies and genomic data. Collaborative research between KAIST and Cambridge can accelerate the analysis of drug efficacy and side effects, and the sharing of complementary expertise for the development of new drugs. If this collaborative research continues, a variety of methodologies for drug development will be developed, as well as contributing to the discovery and understanding of the laws of life science on practical drug efficacy and side effects.
